Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60Leukemia 32Gastrointestinal Stromal Tumors 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 21Blast Crisis 9Philadelphia Chromosome 8Neoplasm Metastasis 8Melanoma 8Lung Neoplasms 8Brain Neoplasms 7Sarcoma 6Prostatic Neoplasms 6Neoplasms 6Recurrence 5Ovarian Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 4Primary Myelofibrosis 4Polycythemia Vera 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myeloid 4Dermatofibrosarcoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3

Interventions

Oxaliplatin 3Ocoxin 3pembrolizumab 2Capecitabine 2penpulimab 1hetrombopag 1golotimod 1durvalumab 1camrelizumab 1aumolertinib 1alectinib 1XELOX 1Surgical Procedures, Operative 1Sunitinib 1Radiotherapy 1Paclitaxel 1Nivolumab 1Immunotherapy 1Imatinib Mesylate 1HhAntag691 1Gemcitabine 1Fluorouracil 1Cyclophosphamide 1Chemoradiotherapy 1Ascorbic Acid 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Digestive System Diseases × Imatinib Mesylate × Clear all
NCT00867113 2018-03-14

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Novartis

Phase 2 Completed
91 enrolled 11 charts
GastrointestinalSarcoma

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡